These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38001033)

  • 81. Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.
    Kim EY; Cho EN; Park HS; Hong JY; Lim S; Youn JP; Hwang SY; Chang YS
    Cancer Biol Ther; 2016; 17(3):237-45. PubMed ID: 26785607
    [TBL] [Abstract][Full Text] [Related]  

  • 82. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
    Arcila ME; Nafa K; Chaft JE; Rekhtman N; Lau C; Reva BA; Zakowski MF; Kris MG; Ladanyi M
    Mol Cancer Ther; 2013 Feb; 12(2):220-9. PubMed ID: 23371856
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.
    Zhou W; Liu Z; Wang Y; Zhang Y; Qian F; Lu J; Wang H; Gu P; Hu M; Chen Y; Yang Z; Zhao R; Lou Y; Han B; Zhang W
    Cancer Med; 2022 Mar; 11(5):1299-1309. PubMed ID: 35023616
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Relationship between EGFR Mutations and Pathological Classification and 
Specimen of Lung Adenocarcinoma].
    Kang L; Zheng J; Zhu X
    Zhongguo Fei Ai Za Zhi; 2017 Jun; 20(6):382-388. PubMed ID: 28641695
    [TBL] [Abstract][Full Text] [Related]  

  • 85. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?
    Han G; Bi J; Tan W; Wei X; Wang X; Ying X; Guo X; Zhou X; Hu D; Zhen W
    Oncotarget; 2016 Aug; 7(35):56998-57010. PubMed ID: 27486770
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.
    Watanabe S; Minegishi Y; Yoshizawa H; Maemondo M; Inoue A; Sugawara S; Isobe H; Harada M; Ishii Y; Gemma A; Hagiwara K; Kobayashi K
    J Thorac Oncol; 2014 Feb; 9(2):189-94. PubMed ID: 24419415
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Clinical value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma.
    Guo Z; Yi F; Yin W; Zhang Y; Li Q; Gu Y; Xiao Y; Cao B; Ma L; Liang L
    Thorac Cancer; 2017 May; 8(3):159-169. PubMed ID: 28220630
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Clinical Characteristics and Prognosis of 76 Lung Adenocarcinoma Patients 
Harboring EGFR Mutations with Pleural Effusion at Initial Diagnosis: 
A Single-center Retrospective Study].
    Yin W; Zhang H; Gu Y; Yi F; Li Q; Liu Y; Yao Y; Liu Z; Cao B
    Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):156-166. PubMed ID: 35340158
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The Frequency and Specific Features of Rare Epidermal Growth Factor Receptor Mutations in Moroccan Patients with Lung Adenocarcinoma whose Tumors harbor positive EGFR mutations.
    El Yacoubi H; Lemine Sow M; El Ghouti M; Kettani F; Gamra L; Mestari A; Jabri L; Elghissassi I; Errihani H
    Gulf J Oncolog; 2020 May; 1(33):40-44. PubMed ID: 32476648
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
    Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
    Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients.
    Sun Y; Yu X; Shi X; Hong W; Zhao J; Shi L
    World J Surg Oncol; 2014 May; 12():148. PubMed ID: 24885205
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
    Ohba T; Toyokawa G; Osoegawa A; Hirai F; Yamaguchi M; Taguchi K; Seto T; Takenoyama M; Ichinose Y; Sugio K
    Surg Today; 2016 Sep; 46(9):1091-8. PubMed ID: 26711128
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.
    Kutsuzawa N; Takahashi F; Tomomatsu K; Obayashi S; Takeuchi T; Takihara T; Hayama N; Oguma T; Aoki T; Asano K
    Tokai J Exp Clin Med; 2020 Sep; 45(3):113-116. PubMed ID: 32901897
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
    Lee VH; Tin VP; Choy TS; Lam KO; Choi CW; Chung LP; Tsang JW; Ho PP; Leung DK; Ma ES; Liu J; Shek TW; Kwong DL; Leung TW; Wong MP
    J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
    Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
    BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
    Yoshida T; Ishii G; Goto K; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Nagai K; Ohe Y; Ochiai A
    J Cancer Res Clin Oncol; 2013 Oct; 139(10):1691-700. PubMed ID: 23974272
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.
    Zhang B; Wang S; Qian J; Yang W; Qian F; Lu J; Zhang Y; Qiao R; Han B
    Cancer; 2018 Jun; 124(11):2399-2406. PubMed ID: 29543321
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.